Literature DB >> 11581089

Hyperammonemia and coma without hepatic dysfunction induced by valproate therapy.

F Barrueto1, J B Hack.   

Abstract

The authors report a case of a 41-year-old mentally disabled man with bipolar disorder who presented to the emergency department with altered mental status. He was found to have a significantly elevated ammonia level (377 microM/L) with no signs of hepatic insufficiency. His coma and hyperammonemia were attributed to his chronic valproate therapy. This patient had the highest serum ammonia level ever reported with a therapeutic valproate level in the absence of any other anticonvulsant therapy, metabolic abnormality, or hepatic dysfunction. The authors discuss this case and review the current literature on hyperammonemia in valproic acid therapy and the use of L-carnitine in these patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11581089     DOI: 10.1111/j.1553-2712.2001.tb01102.x

Source DB:  PubMed          Journal:  Acad Emerg Med        ISSN: 1069-6563            Impact factor:   3.451


  9 in total

Review 1.  Valproate-induced hyperammonaemia superimposed upon severe neuropsychiatric lupus: a case report and review of the literature.

Authors:  Estee Chan; Fiona McQueen
Journal:  Clin Rheumatol       Date:  2012-12-28       Impact factor: 2.980

Review 2.  Clinical practice: the management of hyperammonemia.

Authors:  Johannes Häberle
Journal:  Eur J Pediatr       Date:  2010-12-17       Impact factor: 3.183

3.  Valproate Induced Delirium due to Hyperammonemia in a Case of Acute Mania: A Diagnostic Dilemma.

Authors:  Siddharth Dixit; Mayank Namdeo; Sudip Azad
Journal:  J Clin Diagn Res       Date:  2015-04-01

4.  Comparison of clinical, magnetic resonance and evoked potentials data in a case of valproic-acid-related hyperammonemic coma.

Authors:  Philippe Hantson; Cécile Grandin; Thierry Duprez; Marie-Cécile Nassogne; Jean-Michel Guérit
Journal:  Eur Radiol       Date:  2004-04-29       Impact factor: 5.315

5.  Reversible weakness and encephalopathy while on long-term valproate treatment due to carnitine deficiency.

Authors:  Ahmed Al-sharefi; Rudy Bilous
Journal:  BMJ Case Rep       Date:  2015-09-02

6.  Valproate-induced encephalopathy with predominant pancerebellar syndrome.

Authors:  Rajesh Verma; Prakash Kori
Journal:  Indian J Pharmacol       Date:  2012-01       Impact factor: 1.200

Review 7.  Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence?

Authors:  Philippe E R Lheureux; Andrea Penaloza; Soheil Zahir; Mireille Gris
Journal:  Crit Care       Date:  2005-06-10       Impact factor: 9.097

8.  Non-Hyperammonemic valproate encephalopathy.

Authors:  Omar Farooq; Pervaiz M Zunga; Mohd I Dar; Abdul Q Rather; Samia Rashid; Javid Basu; Ishrat H Dar; Mohd Ashraf
Journal:  Ann Neurosci       Date:  2014-04

9.  Levocarnitine for valproate-induced hyperammonemia in the psychiatric setting: A case series and literature review.

Authors:  Lauren M Brown; Nicole Cupples; Troy A Moore
Journal:  Ment Health Clin       Date:  2018-04-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.